ARCHIVES

CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.

This article is from The Cancer Letter archive.

Vol. 30 No. 42 | November 5, 2004

Download PDF Visit The Full Archive

Related Articles

NSABP’s Pink Sheet; Fisher’s Control Had A Downside, Review Said

June 24, 1994

Women PIs Score Highest In RFA To Encourage Early Breast Cancer Detection

May 1, 1987

FDA Auditors Spend Two Weeks At Duke, Nevins Loses Position in Reorganization

January 28, 2011

ASCO Updates Guideline On Use Of Tumor Markers

October 27, 2006

In Brief: John Kovach Succeeds Moertel As Mayo CC Head; DEA Deputy Appointed; New NCAB Member Named

February 7, 1986

Efaproxyn Improved Survival Of Patients With Brain Mets

October 29, 2004